Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News PLUS THERAPEUTICS Inc. PSTV

Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focused on the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:PSTV)

Fundamentals Snapshot (NDAQ:PSTV)

Current News (NDAQ:PSTV)

Plus Therapeutics Provides Updates on ReSPECT(TM) Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

GlobeNewswire November 19, 2022

Plus Therapeutics to Provide Update on ReSPECT(TM) Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

GlobeNewswire November 2, 2022

Plus Therapeutics Announces Selection of "Rhenium (186Re) Obisbemeda" as International Non-Proprietary Name for 186RNL

GlobeNewswire October 26, 2022

Plus Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

GlobeNewswire October 20, 2022

Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress

GlobeNewswire October 19, 2022

Plus Therapeutics to Present at the ThinkEquity Conference

GlobeNewswire October 18, 2022

Plus Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on October 20, 2022

GlobeNewswire October 6, 2022

Plus Therapeutics Announces Patient Webinar in Recognition of Breast Cancer Awareness Month

GlobeNewswire October 5, 2022

Plus Therapeutics to Share Data in Oral Presentations from Ongoing ReSPECT(TM) Clinical Trials at the 35th Annual Congress of the European Association of Nuclear Medicine

GlobeNewswire October 4, 2022

Opinion & Analysis (NDAQ:PSTV)

Plus Therapeutics Shares Trade Higher on Q3 Earnings and Business Restructuring

Streetwise Reports November 18, 2019

What Stephen Hawking Missed: ...

Streetwise Reports May 2, 2018

Companies flocking to Japan for biotech deals

The Life Sciences Report February 2, 2017

Bullboard Posts (NDAQ:PSTV)

I guess there is t anyone talking about this stock

Crickets.  Well I like this stock!!  Join me!!
Chester55 - August 21, 2021

In some here....

Cheers !
Iseneschal - February 11, 2021

still holding this stock

used dollar cost averaging for it after getting caught by an upswing followed by a cheap stock financing,so glta shareholders but it...
coolfooldumbguy - December 16, 2019

it's a buy today for me

my last batch at these low prices,so glta shareholders.
coolfooldumbguy - September 25, 2019

still holding this stock

adding more shares this morning after the cheap financing yesterday collapsed the stock price, using dollar cost averaging on this one,so...
coolfooldumbguy - September 24, 2019

the bottom is past for

people playing with it all day but its value is $16 per share,so glta shareholders.
coolfooldumbguy - September 23, 2019